Machine Learning-Guided Engineering of Protease Modulators
Machine Learning-Guided Engineering of Protease Modulators
批准号:
10353932
负责人:
Carl Denard
金额:
$21.94万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-02-01 至 2023-08-31
关键词:
Active SitesAddressAffinityAlgorithmsAntibodiesAutoimmune DiseasesAutoimmunityBacteriophagesBindingBiochemicalBiomedical ResearchBypassCOVID-19ClinicalColorCommunicable DiseasesConsumptionCysteineDNA sequencingDataData SetDevelopmentDiseaseEngineeringEnzymesEpitope MappingEpitopesFluorescence PolarizationFluorescence-Activated Cell SortingFoundationsFutureGenetic TranscriptionGoalsGuidelinesHepatitis C virusHomeostasisInfectionInsulinaseLeadLengthLibrariesLigand BindingLigandsMMP2 geneMachine LearningMalignant NeoplasmsMapsMatrix MetalloproteinasesMethodsModelingNerve DegenerationPeptide HydrolasesPharmaceutical PreparationsPhenotypePhysiologicalProcessPropertyProtease InhibitorProteinsPublic HealthReporterResearchSerine ProteaseSiteStructureTechnologyThermodynamicsTimeToxic effectTrainingWorkYeastsbasebeta secretasebeta-site APP cleaving enzyme 1convolutional neural networkdesignexperimental studyfunctional outcomesgenetic selectionhigh dimensionalityhigh throughput screeningin silicoinhibitorinterestmachine learning algorithmmathematical modelmicrobialnanobodiesnew technologynext generationnovelside effectsmall moleculesmall molecule inhibitortherapeutic targettool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Modulating the activity of proteases is a central strategy for treating cancer, autoimmunity, and infection. However, the
discovery and design of selective and potent therapeutics targeting proteases (small-molecules and antibodies) largely rely
on inefficient, iterative processes. As a result, it takes several years to develop a protease drug, and even then, most protease
drugs are active site inhibitors that often suffer from low selectivity in distinguishing related proteases. Due to the
complexity of proteolytic dysregulation, restoring homeostasis requires not only selective inhibitors but also ligands that
can reprogram protease selectivity. Unfortunately, no platform exists to engineer protease modulators based on systematic,
and quantitative design principles.
To address these challenges, this proposal seeks to combine for the first time Machine Learning tools, Next-
Generation DNA sequencing, and a yeast-based high-throughput functional screen to accelerate the isolation and
design of nanobody-based protease modulators. The functional selection will perform two tasks: (i) select nanobodies
from synthetic libraries based on a desired function and (ii) correlate ligand: epitope interactions to a functional outcome.
These experiments will generate high-quality datasets that will train machine learning algorithms (ML) to predict the
potency, selectivity, and mechanisms of nanobody-based modulators based on their sequence features alone.
This machine learning-aided strategy will accelerate the discovery of rare and potent protease modulators and
bypass the limitations of structure-based methods. Moreover, curated datasets of protease modulatory nanobody sequences
will provide reference and design guidelines for future experimental and in silico campaigns. This work is of significant
interest to biomedical research and public health and includes select proteases such as Hepatitis C virus protease, MMPs,
transmembrane serine protease 2 (COVID-19), β-secretase, and insulin-degrading enzyme. Moreover, the proposed studies
provide a foundation to answering fundamental biochemical questions on how synthetic ligands can map and modulate the
functional landscape of proteases and other protein-modifying enzymes.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Reprogramming proteases: tackling human diseases with next-generation modulators
-
批准号:10709575
-
项目类别:
-
资助金额:$27.19万
-
财政年份:2022
-
负责人:Carl Denard
-
依托单位:
AWD13299 Admin Supplement to Support Undergraduate Summer Research Experiences
-
批准号:10808664
-
项目类别:
-
资助金额:$1.01万
-
财政年份:2022
-
负责人:Carl Denard
-
依托单位:
海外基金